已发表论文

CpG 寡脱氧核苷酸与抗 4-1BB 抗体联合治疗小鼠多发性肝细胞癌

 

Authors Ma S, Yang X, Zhou H, Zhang C, Kang J, Sun D

Received 6 May 2020

Accepted for publication 30 June 2020

Published 20 July 2020 Volume 2020:13 Pages 6997—7005

DOI https://doi.org/10.2147/OTT.S260353

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Leo Jen-Liang Su

Background: To investigate the effect of topical application of CpG oligodeoxynucleotide (CpG-ODN) combined with anti-4-1BB antibodies on mouse HCC multiple tumor-bearing models and the degree of improvement of anti-tumor immune response in mice.
Materials and Methods: We inoculated each BALB/c male mouse subcutaneously with one tumor in the axillae of the four limbs and divided them into four groups. We only selected the tumor-bearing part of the left lower limb for drug treatment. We measured the tumor-bearing volume of mice in each group. Then, we tested the organ coefficients of mice, the concentrations of IL-12 and IFN-γ in peripheral blood, the ratio of spleen Tregs and CD8+T cells, the spleen CTL killing activity, and the survival time of mice.
Results: We found that the tumor-bearing volume decreased significantly after the combination of CpG-ODN and anti-4-1BB antibody (< 0.001). The organ coefficients of treated mice were not significantly different from normal mice (> 0.05). The concentration of IL-12 and IFN-in serum and the ratio of CD8+T cells in spleen were increased, while the ratio of spleen Tregs was decreased. CTL activity of spleen was increased. The survival time of mice was significantly prolonged (< 0.001).
Conclusion: The treatment programme combining CpG-ODN with an anti-4-1BB antibody can significantly reduce tumor growth at the treatment site, slow the growth rate of metastases and improve host prognosis.
Keywords: hepatocellular carcinoma, 4-1BB, CpG-ODN, immunity therapy




Figure 1 CpG-ODN combined with the anti-4-1BB antibody significantly reduced...